66th Annual American Society of Hematology Annual Meeting and Exposition – (Multiple Myeloma) – November 2024
Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Shlomo Elias, MD, PhD, Sigal Grisariu, MD, Batia Avni, MD, Miri Assayag, Tali Dubnikov-Sharon, Rivka Alexander-Shani, Nomi Bessig, Alaa Shehadeh, Aseel Ishtay, Shelly Pimienta, Vladimir Vaistein, Eran Zimran, Marjorie Pick, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Polina Stepensky and Moshe E Gatt, MD. 66th ASH Annual Meeting and Exposition, San Diego, CA, December 2024.
Phase 1/2 – Multiple Myeloma 50 patients at 800M cells
S. Kfir-Erenfeld, N. Asherie, E. Lebel, V. Vainstein, M. Assayag, S.T. Dubnikov, S. Grisariu, B. Avni, S. Elias, R. Alexander-Shani, N. Bessig, A. Shehadeh, A. Ishtay, V. Zelmanovich, E. Zimran, M. Pick, I. Roziner, R.S. Kenett, Y.C. Cohen, I. Avivi, C.J. Cohen, M.E.E. Gatt, P. Stepensky. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma. Blood Adv. 2024 May 20:bloodadvances.2024012967. doi: 10.1182/bloodadvances.2024012967. Epub ahead of print. PMID: 38768428.
ASH – 65th Annual American Society of Hematology Annual Meeting and Exposition – (Multiple Myeloma) – Dec 11, 2023
Lebel, N. Asherie, S. Kfir Erenfeld, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, A. Shaulov, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Safety and efficacy of a locally produced novel anti-BCMA Chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma. 65th ASH Annual Meeting and Exposition, San Diego, CA. Dec 11, 2023
ASH – 65th Annual American Society of Hematology Annual Meeting and Exposition – (Multiple Myeloma) – October 2023
Lebel, N. Asherie, S. Kfir Erenfeld, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, A. Shaulov, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Safety and efficacy of a locally produced novel anti-BCMA Chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma. 65th ASH Annual Meeting and Exposition, San Diego, CA. October 2023
IMS – International Myeloma Society – 20th Annual Meeting – (Multiple Myeloma) – Sep 27-30, 2023
Lebel, N. Asherie, S. Kfir Erenfeld, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, A. Shaulov, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Gatt. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. Sep 27-30 2023.
European Society for Blood and Marrow Transplantation 49th Annual Meeting – Apr 23-26, 2023
Assayag , N. Asherie, S. Kfir Erenfeld, B. Avni, T. Dubnikov, N. Zalcman, E. Lebel, E. Zimran, A. Shaulov, M. Pick, Y. Cohen, I. Avivi, C. Cohen, M. Gatt, S. Grisariu, P. Stepensky. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting. 2023 Apr 23-26.
5th European CAR T-cell Meeting – 47 Patient Clinical Data Poster Presentation – Feb 9-11, 2023
Assayag M, Asherie N, Kfir-Erenfeld S, Avni B, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S, Stepensky P. Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11.
Phase 1 – Multiple Myeloma
Asherie N, Kfir-Erenfeld S, Avni B, Assayag M, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S, Stepensky P. Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.
EDITORIAL PUBLICATION
Editorial – Sjöstrand M, Sadelain M. Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma. Haematologica. 2023. doi: 10.3324/haematol.2022.282053. Epub ahead of print. PMID: 36794501. (PDF link)
Preclinical
Harush O, Asherie N, Kfir-Erenfeld S, Adler G, Barliya T, Assayag M, Gatt ME, Stepensky P, Cohen CJ. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. Haematologica. 2022 Oct 1;107(10):2395-2407. doi: 10.3324/haematol.2021.280169. PMID: 35354252; PMCID: PMC9521250.